sgp130 in Chronic Human Liver Disease

Completed

• Conditions: Alcoholic Liver Disease; Chronic Hepatitis C Virus Infection

• Registration Number: NCT00770198
• Lead Sponsor: Erasme University Hospital

Brief Summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Detailed Description

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Study Timeline

• Study Start: 2005-01
• Primary Completion: 2007-01
• Status Verified: 2008-10
• Study Completion: 2008-10
• Study First Submitted: 2008-10-08
• Study First Submitted QC: 2008-10-08
• Last Update Submitted: 2008-10-08
• Study First Posted: 2008-10-09
• Last Update Posted: 2008-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 129

Inclusion Criteria

• Alcohol excess intake and suspected liver disease
• Alcohol excess intake and clinical liver cirrhosis
• chronic hepatitis C virus infection and suspected liver disease
• chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria

• other (superimposed) liver disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Hopital Erasme - Dpt of Gastroenterology; 🇧🇪 Brussels, Belgium